Literature DB >> 26960924

The normal-weight type 2 diabetes phenotype revisited.

Michel P Hermans1, K Daniel Amoussou-Guenou2, Evariste Bouenizabila3, Shaukat S Sadikot4, Sylvie A Ahn5, Michel F Rousseau5.   

Abstract

BACKGROUND: Type 2 diabetes (T2DM) is associated with obesity, insulin resistance and the metabolic syndrome (MetS). In non-diabetic populations, features of metabolic obesity (MO) are observed in a minority of normal-weight (NW) subjects. The cardiometabolic status of metabolically obese but normal-weight (MONW) individuals has not yet been phenotyped in T2DM. PATIENTS AND METHODS: Prevalence and features of MONW were analyzed in 1244 T2DM patients, in whom MONW was identified as a BMI <25.0 and a MetS score ≥3/5. Among NW (n=262; 21%), those without MetS (n=152; NW-MetS[-]) were compared to NW-MetS[+] (n=110; i.e. 42% of NW and 9% of all T2DM).
RESULTS: There were no differences between groups in age; gender; diabetes duration; smoking; BP; and LDL-C. NW-MetS[+] had higher BMI; waist; fat mass; visceral fat; liver steatosis and HbA1c, and lower insulin sensitivity. Non-right-handedness was twice-higher (18%) in NW-MetS[-]. NW-MetS[+] had higher apoB100 and triglycerides, and lower HDL-C and LDL size. Macroangiopathy was present in 39% of NW-MetS[+] vs. 22% of NW-MetS[-], as coronary (23% vs. 14%) or peripheral artery disease (14% vs. 5%) and TIA/stroke (15% vs. 7%). Microangiopathy was present in 54% of NW-MetS[+] vs. 32% of NW-MetS[-], as retinopathy (25% vs. 13%); neuropathy (29% vs. 18%); and albuminuria (39% vs. 20%).
CONCLUSIONS: MONW among T2DM represents a significant minority (about 1 in 10). Their cardiometabolic phenotype deserves attention due to multiple comorbidities, including a twice-higher prevalence of micro-/macrovascular damage in patients wrongly perceived at lower risk due to normal BMI. Unexpectedly, non-right-handedness was over-represented among metabolically healthy patients.
Copyright © 2016 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atherogenic dyslipidemia; Diabetes; Handedness; Metabolic syndrome; Obesity

Mesh:

Substances:

Year:  2016        PMID: 26960924     DOI: 10.1016/j.dsx.2016.01.035

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  5 in total

Review 1.  Mediators of diabetic neuropathy: is hyperglycemia the only culprit?

Authors:  Anna Grisold; Brian C Callaghan; Eva L Feldman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-04       Impact factor: 3.243

2.  Active smoking among people with diabetes mellitus or hypertension in Africa: a systematic review and meta-analysis.

Authors:  Jean Jacques Noubiap; Jobert Richie Nansseu; Francky Teddy Endomba; Anderson Ngouo; Jan René Nkeck; Ulrich Flore Nyaga; Arnaud D Kaze; Jean Joel Bigna
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 3.  Obesity subtypes, related biomarkers & heterogeneity.

Authors:  Laura Perez-Campos Mayoral; Gabriel Mayoral Andrade; Eduardo Perez-Campos Mayoral; Teresa Hernandez Huerta; Socorro Pina Canseco; Francisco J Rodal Canales; Héctor Alejandro Cabrera-Fuentes; Margarito Martinez Cruz; Alma Dolores Pérez Santiago; Juan José Alpuche; Edgar Zenteno; Hector Martínez Ruíz; Ruth Martínez Cruz; Julia Hernandez Jeronimo; Eduardo Perez-Campos
Journal:  Indian J Med Res       Date:  2020-01       Impact factor: 2.375

4.  Determinants of Metabolic Syndrome and Type 2 Diabetes in the Absence of Obesity: The Jackson Heart Study.

Authors:  Morgana Mongraw-Chaffin; Santiago Saldana; Mercedes R Carnethon; Haiying Chen; Valery Effoe; Sherita Hill Golden; Joshua Joseph; Rita R Kalyani; Alain G Bertoni
Journal:  J Endocr Soc       Date:  2022-04-09

5.  Impact of the Dynamic Change of Metabolic Health Status on the Incident Type 2 Diabetes: A Nationwide Population-Based Cohort Study.

Authors:  Jung A Kim; Da Hye Kim; Seon Mee Kim; Yong Gyu Park; Nan Hee Kim; Sei Hyun Baik; Kyung Mook Choi; Kyungdo Han; Hye Jin Yoo
Journal:  Endocrinol Metab (Seoul)       Date:  2019-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.